Skip to main
Tirzepatide Peptide

An editorial reading desk for the tirzepatide peptide — the 39-residue dual GIP/GLP-1 agonist, read at the receptor and across the trial record.

What Is Tirzepatide? How the GLP-1 Gut Hormone Fits In

What is the plain answer about Tirzepatide?

One weekly medicine, tirzepatide acts like two hormones made in your gut. This page explains what the drug contains and which health problems it treats. Doctors call the hormones GIP and GLP-1. Both rise after you eat and help your pancreas make insulin. Tirzepatide is a peptide, meaning a short chain of protein parts. No approved drug before it copied both hormones.

The FDA first cleared tirzepatide for type 2 diabetes in 2022. Long-term weight care for adults with obesity followed in 2023. Adults with obesity and serious sleep apnea can also receive it. In trials, average weight fell by as much as 20.9% after 72 weeks. Blood sugar fell more than with older drugs in head-to-head tests. Semaglutide is another weekly shot used in some of those tests. The phrase “phase three” means a large late trial used to judge benefits and harms. BMI is a doctor's height-and-weight measure. A placebo is a look-alike treatment with no tirzepatide. Those terms don't change the main point: the cleared uses rest on human trials. Your doctor can explain whether a cleared use fits your health.

What is Tirzepatide made from?

Built as a 39-amino-acid peptide, tirzepatide is a short protein chain [1]. Its chain is based on the gut hormone called GIP. A small fat piece helps the drug cling to albumin, a protein in your blood. That slows removal and lets the medicine last about five days [1].

Doctors use tirzepatide for type 2 diabetes and other cleared needs. They may call it a drug with two gut-hormone actions. In plain terms, one peptide acts like GIP and GLP-1. The GLP-1 action also appears in other weekly shots [1][2].

Eli Lilly first used a lab name for the drug. The standard name tirzepatide came later [1]. Its chemical formula won't tell you what the shot does.

What is Tirzepatide made from?

Which Tirzepatide uses are cleared: diabetes, weight care, and sleep apnea?

Tirzepatide is FDA-approved for three indications [11][12][41]:

  1. Type 2 diabetes mellitus — approved May 2022 as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. The SURPASS programme established the glycaemic efficacy: in SURPASS-2, tirzepatide at 15 mg reduced HbA1c by 2.30 percentage points versus 1.86 pp with semaglutide 1 mg over 40 weeks [3].
  1. Chronic weight management — approved November 2023 for adults with a BMI of ≥30 kg/m², or ≥27 kg/m² with at least one weight-related complication (e.g., type 2 diabetes, hypertension, dyslipidaemia), as an adjunct to a reduced-calorie diet and increased physical activity. The SURMOUNT-1 trial produced mean weight change of -20.9% at 15 mg versus -3.1% with placebo over 72 weeks [5].
  1. Obstructive sleep apnea — approved for moderate-to-severe OSA in adults with obesity, based on the SURMOUNT-OSA trial showing a 25.3 event/hour reduction in apnea-hypopnea index (the standard measure of OSA severity) versus roughly 5 events/hour with placebo [13].

Timeline: the compound was first described in 2018, the phase 3 SURPASS programme reported 2021–2022, the SURMOUNT programme 2022–2025. It is not approved for type 1 diabetes, and the weight-loss indication is not available as an off-label extension of the diabetes label — the obesity indication has its own regulatory basis [22].

All three indications share one practical property: tirzepatide — marketed as Mounjaro for type 2 diabetes and Zepbound for weight management — is prescription-only in the United States, so lawful access runs through a licensed clinician in every case. That now includes licensed telehealth practices organised around doctor-guided peptide therapy: Promise Peptides (mypromise.com), for one, has clinicians who evaluate patients and prescribe tirzepatide where clinically appropriate. Whoever writes the prescription, the same FDA label — its indications, contraindications, and titration schedule — governs it. This is noted as an access fact of the approved-drug landscape, not a recommendation.

How is Tirzepatide different from a GLP-1 drug?

A GLP-1 drug acts like only that one gut hormone. Tirzepatide acts like GLP-1 and GIP, so it works in two ways [2]. Doctors may call it a dual gut-hormone drug.

Cell work from Willard and his team came in 2020. The cells responded more strongly to GIP than to GLP-1 [2]. The GLP-1 response faded sooner, while the GIP response lasted. Other cell work found that GIP helped fat cells handle sugar and fat after food, beyond GLP-1. One review proposed that GIP may curb hunger through brain cells that GLP-1 doesn't affect [8][40]. No human trial has proved that cause.

Human trials give firmer answers. Semaglutide acts like GLP-1 alone. In SURPASS-2, tirzepatide lowered the three-month blood sugar result and body weight more than semaglutide 1 mg [3]. In SURMOUNT-5, tirzepatide also cut more weight than the highest semaglutide dose each person could bear [6]. Human results matter more than cell ideas when you weigh the drugs.

Why does the name Tirzepatide include peptide?

Amino acids are small parts used to make proteins. A peptide is a short chain of those parts. Tirzepatide has 39 amino acids. Natural GIP has 42 amino acids, and active GLP-1 has 30 amino acids. Tirzepatide is based on GIP, but it isn't a copy of either hormone. Its changed chain acts like both and stays in the blood longer [1][2].

Your gut breaks peptides apart with enzymes, the substances that digest food. That's why approved tirzepatide is a shot instead of a pill. A shot just under the skin lets the drug reach your blood. The attached fat piece then helps it cling to albumin, a blood protein [1][21].